Home » Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma

Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma

Jul 30, 2009
Premium

By Doug Macron

This article has been updated to include comments from Quark's CEO.

Quark Pharmaceuticals expects to file an investigational new drug application for its siRNA-based eye-disease treatment QPI-1007 sometime in September, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

May
08
Featured Webinar

Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue

Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

What's Popular?

In Gene Silencing/Gene Editing

  1. Taconic Biosciences Licenses Easi-CRISPR Tech

  2. Researchers Identify Essential Genes for Pluripotent Stem Cells Through CRISPR-Cas9 Screening

  3. Chemotherapy Resistance Pathway for AML Identified in CRISPRa Screen

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.